Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,548.00
(
1.89%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
77,653.82
(
0.24%
)
News Focus
News Focus
Post# of 822788
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

flipper44

Send PM Follow Ignore
Followers 308
Posts 37305
Boards Moderated 1
Alias Born 11/14/2013

flipper44

Member Level

Re: exwannabe post# 134152

Wednesday, 09/13/2017 1:24:03 PM

Wednesday, September 13, 2017 1:24:03 PM

Post# of 822788
Exwannabe, I totally agree with your post.

SoS concludes the other 2 trials show why NWBO needs to run the DCVax-L trial well past planned endpoint analysis. The argument is it needs the data. Yet the two comp trials were successful at substantially shorter early stops. -- exwannabe

Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News